Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director Daniel K. Spiegelman received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036. They vest and become fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SPIEGELMAN DANIEL K

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 18,000 options Exercise price: $23.58 per share Underlying shares: 18,000 shares +2 more

5 metrics

Options granted 18,000 options Stock Option (Right to Buy) grant to director

Exercise price $23.58 per share Stock option strike price for underlying common stock

Underlying shares 18,000 shares Common stock underlying granted options

Total derivative holdings after grant 18,000 options Total stock options held following this transaction

Option expiration June 7, 2036 Expiration date of granted stock options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual stockholders meeting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 23.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-07T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual stockholders meeting financial

"the issuer's 2027 annual stockholders meeting"

vest financial

"The option shall vest and be fully exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SPIEGELMAN DANIEL K

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.58	06/08/2026		A		18,000		(1)	06/07/2036	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Maze Therapeutics (MAZE) director Daniel Spiegelman report on this Form 4?

Maze Therapeutics director Daniel K. Spiegelman reported receiving a grant of stock options for 18,000 shares of common stock. These options were awarded as compensation, not purchased in the open market, and reflect a new derivative position rather than a cash transaction.

How many Maze Therapeutics (MAZE) stock options were granted and at what price?

Daniel Spiegelman was granted stock options on 18,000 shares of Maze Therapeutics common stock. The options have an exercise price of $23.58 per share, meaning he can buy shares at that price once the options vest and become exercisable.

When do Daniel Spiegelman’s Maze Therapeutics (MAZE) options vest and become exercisable?

The granted options vest and become fully exercisable on the earlier of the issuer’s 2027 annual stockholders meeting or June 8, 2027. Vesting is contingent on Daniel Spiegelman’s continued service to Maze Therapeutics through that vesting date.

What is the expiration date of the Maze Therapeutics (MAZE) stock options granted to Daniel Spiegelman?

The stock options granted to Daniel Spiegelman expire on June 7, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Maze Therapeutics common shares at the specified exercise price.

Is the Maze Therapeutics (MAZE) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 shows a compensation-related grant, not an open‑market purchase. The transaction code is “A,” indicating a grant, award or other acquisition of derivative securities, specifically stock options, with no cash price paid at the time of grant.